Medicenna Therapeutics Corp.

Medicenna Therapeutics Corp. is a clinical-stage immunotherapy company based in Toronto, Ontario, Canada, with a wholly-owned subsidiary in Houston, Texas. The company's core business revolves around the development and commercialization of novel, highly selective versions of Interleukin-2 (IL-2), IL-4, and IL-13 Superkines and first-in-class Empowered Superkines. Utilizing directed evolution and AI-driven rational design, Medicenna re-engineers natural interleukins to precisely modulate immune responses, aiming to deliver first- and best-in-class treatment options for cancer and other serious immune-driven diseases, including autoimmune and inflammatory disorders.

The company's pipeline is built upon its proprietary Superkine™, BiSKIT™, and T-MASK™ platforms. Key product candidates include MDNA11, a long-acting IL-2 super-agonist currently in a Phase 1/2 ABILITY-1 study for various solid tumors. Bizaxofusp (MDNA55), an IL-4 Superkine therapy for high-grade glioma, including recurrent glioblastoma (rGBM), is Phase 3-ready and holds Fast Track and Orphan Drug status from the FDA/EMA, with Medicenna actively seeking strategic partners for its advancement. Other candidates include MDNA113, a tumor-targeting and activatable masked anti-PD-1-IL-2 BiSKIT™ for solid tumors, and MDNA209 and MDNA413, which are super antagonists targeting autoimmune and inflammatory diseases, respectively.

Dr. Fahar Merchant serves as the President, CEO, and Chairman of the Board, a position he has held since October 2011. In April 2026, Dr. Nageatte Ibrahim was appointed Chief Medical Officer, bringing extensive oncology and clinical development expertise to the team. Recent notable activities include the presentation of positive data for MDNA113 at AACR 2026 and an upcoming presentation on the NEO-CYT Trial (MDNA11 in melanoma) at ASCO 2026. Medicenna's 2026 outlook emphasizes maximizing MDNA11's potential, advancing MDNA113, and securing partnerships for bizaxofusp, underscoring its commitment to progressing its clinical-stage immunotherapy programs.

Latest updates

Medicenna's NEOCYT Melanoma Trial Data Presentation Looms at ASCO 2026

Event summary

  • Medicenna Therapeutics and Fondazione Melanoma Onlus will present a poster on the NEOCYT trial at the ASCO 2026 conference in Chicago, May 31st.
  • The NEOCYT trial is a Phase 1b study evaluating MDNA11, a Superkine IL-2 variant, in combination with nivolumab and potentially ipilimumab for high-risk melanoma patients.
  • The trial is investigator-initiated and sponsored by Fondazione Melanoma Onlus at the National Cancer Institute 'G. Pascale Foundation'.
  • MDNA11 is designed to preferentially activate cancer-killing immune cells while minimizing immunosuppressive effects.

The big picture

The NEOCYT trial represents a strategic pivot for Medicenna, focusing on a novel approach to IL-2 therapy designed to overcome the toxicity and limited efficacy of earlier iterations. The partnership with Fondazione Melanoma Onlus, a respected Italian melanoma research organization, lends credibility to the trial and expands Medicenna’s reach in the European oncology market. Success in this trial could significantly de-risk MDNA11 and accelerate its path to commercialization, but failure would likely necessitate a reassessment of the Superkine platform’s viability.

What we're watching

Clinical Efficacy
The ASCO presentation will be critical in assessing whether the combination of MDNA11 with existing therapies demonstrates meaningful clinical benefit in a high-risk melanoma population, particularly given the challenges in overcoming resistance to checkpoint inhibitors.
Regulatory Pathway
The trial's design and early data will influence the potential for accelerated regulatory approval pathways, especially given the unmet need for more effective melanoma treatments and the Fast Track/Orphan Drug designations for bizaxofusp.
Competitive Landscape
The NEOCYT trial’s results will be weighed against the performance of other novel IL-2 variants and combination immunotherapies in development, impacting Medicenna’s ability to secure partnerships and maintain a competitive edge.
CID: 968